BioSpace News Archive

Foothill Regional Medical Center announced it has reached the milestone of 300 robotic-assisted surgeries using da Vinic Xi and Mako SmartRobotics.

Lexicon Pharmaceuticals, Inc. announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit in Washington, D.C.

VBL Therapeutics, a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Appili Therapeutics Inc. today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”) in partnership with the U.S. Air Force Academy (“USAFA”), will provide at least US$14 million in funding over two years to fund the development of ATI-1701.

Oramed Pharmaceuticals Inc. today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co., Ltd., an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.

MoonLake Immunotherapeutics announced its financial results for the quarter ended September 30, 2022, and provided a business update.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2022.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.

Q BioMed Inc. is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc., a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada.